COMPANY OVERVIEW

Accutar is a clinical stage biotech company focused on AI-empowered drug discovery, and its application to the discovery and development of clinically differentiated medicines.

---

LOCATION

---

THERAPEUTIC AREAS

---

WEBSITE

https://www.accutarbio.com.

---

CAREER WEBSITE

None

---

SOCIAL MEDIA

---

INVESTORS

---

PRESS RELEASES

Jun 20, 2023

Accutar Biotechnology Announces First Patient Dosed with AC0676 in Phase 1 Study in Patients with Relapsed/Refractory B-cell Malignancies

Feb 23, 2023

Accutar Biotechnology Announces First Patient Dosed in China with AC0176 in Phase 1 Study in Prostate Cancer

Feb 3, 2023

Accutar Biotechnology Announces FDA Clearance of IND Application for Phase 1 Trial of AC0676 in B-cell Malignancies

Aug 19, 2022

Accutar Biotechnology Receives NMPA Clearance of IND Application for AC0176 in Prostate Cancer

Jun 1, 2022

Accutar Biotechnology Announces Fast Track Designation Granted by FDA to AC0176 for the Treatment of Metastatic Castration-Resistant Prostate Cancer

For More Press Releases

---